Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist

Ken Ichi Tanaka, Ikuko Miyazaki, Naoko Fujita, Md Emdadul Haque, Masato Asanuma, Norio Ogawa

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We have previously reported that ropinirole, a non-ergot dopamine agonist, has neuroprotective effects against 6-hydroxydopamine in mice based on in vivo antioxidant properties such as the glutathione (GSH)-activating effect. In the present study, we determined that the effects of ropinirole on the level of expression of GSH-related enzyme mRNA, these enzymes were shown to regulate GSH contents in the brain. This study focused on the mechanism of GSH enhancement by ropinirole. Striatal GSH contents were significantly increased by 7-day daily administration of ropinirole. Furthermore, the expression levels of γ-glutamylcysteine synthetase (γ-GCS), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST) mRNA increased following daily injections of ropinirole for 7 days. In addition, ropinirole treatment for 7 days suppressed auto-oxidation in mouse striatal homogenates, in contrast to the vehicle treatment. In conclusion, ropinirole was able to suppress auto-oxidation, most probably by increasing GSH levels due to an increase of GSH synthesis. In addition, it is likely that auto-oxidation was also suppressed by the activation of GSH-regulating enzymes such as GPx, GR, and GST in the mouse striatum. Thus, our results indicate that the GSH-activating effect of ropinirole may render this dopamine agonist beneficial as a neuroprotective drug.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalNeurochemical Research
Volume26
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Dopamine Agonists
Glutathione
Dopamine
Chemical activation
Corpus Striatum
Glutathione Reductase
Neuroprotective Agents
Glutathione Peroxidase
Glutathione Transferase
Oxidation
Enzymes
Glutamate-Cysteine Ligase
Messenger RNA
ropinirole
Oxidopamine
Brain
Antioxidants
Injections
Therapeutics

Keywords

  • Dopamine D2 agonist
  • Glutathione
  • Non-ergot derivative
  • Ropinirole

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry

Cite this

Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. / Tanaka, Ken Ichi; Miyazaki, Ikuko; Fujita, Naoko; Haque, Md Emdadul; Asanuma, Masato; Ogawa, Norio.

In: Neurochemical Research, Vol. 26, No. 1, 2001, p. 31-36.

Research output: Contribution to journalArticle

Tanaka, Ken Ichi ; Miyazaki, Ikuko ; Fujita, Naoko ; Haque, Md Emdadul ; Asanuma, Masato ; Ogawa, Norio. / Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. In: Neurochemical Research. 2001 ; Vol. 26, No. 1. pp. 31-36.
@article{b988959e60854f9ea264c4c72a7c29d7,
title = "Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist",
abstract = "We have previously reported that ropinirole, a non-ergot dopamine agonist, has neuroprotective effects against 6-hydroxydopamine in mice based on in vivo antioxidant properties such as the glutathione (GSH)-activating effect. In the present study, we determined that the effects of ropinirole on the level of expression of GSH-related enzyme mRNA, these enzymes were shown to regulate GSH contents in the brain. This study focused on the mechanism of GSH enhancement by ropinirole. Striatal GSH contents were significantly increased by 7-day daily administration of ropinirole. Furthermore, the expression levels of γ-glutamylcysteine synthetase (γ-GCS), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST) mRNA increased following daily injections of ropinirole for 7 days. In addition, ropinirole treatment for 7 days suppressed auto-oxidation in mouse striatal homogenates, in contrast to the vehicle treatment. In conclusion, ropinirole was able to suppress auto-oxidation, most probably by increasing GSH levels due to an increase of GSH synthesis. In addition, it is likely that auto-oxidation was also suppressed by the activation of GSH-regulating enzymes such as GPx, GR, and GST in the mouse striatum. Thus, our results indicate that the GSH-activating effect of ropinirole may render this dopamine agonist beneficial as a neuroprotective drug.",
keywords = "Dopamine D2 agonist, Glutathione, Non-ergot derivative, Ropinirole",
author = "Tanaka, {Ken Ichi} and Ikuko Miyazaki and Naoko Fujita and Haque, {Md Emdadul} and Masato Asanuma and Norio Ogawa",
year = "2001",
doi = "10.1023/A:1007672414239",
language = "English",
volume = "26",
pages = "31--36",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist

AU - Tanaka, Ken Ichi

AU - Miyazaki, Ikuko

AU - Fujita, Naoko

AU - Haque, Md Emdadul

AU - Asanuma, Masato

AU - Ogawa, Norio

PY - 2001

Y1 - 2001

N2 - We have previously reported that ropinirole, a non-ergot dopamine agonist, has neuroprotective effects against 6-hydroxydopamine in mice based on in vivo antioxidant properties such as the glutathione (GSH)-activating effect. In the present study, we determined that the effects of ropinirole on the level of expression of GSH-related enzyme mRNA, these enzymes were shown to regulate GSH contents in the brain. This study focused on the mechanism of GSH enhancement by ropinirole. Striatal GSH contents were significantly increased by 7-day daily administration of ropinirole. Furthermore, the expression levels of γ-glutamylcysteine synthetase (γ-GCS), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST) mRNA increased following daily injections of ropinirole for 7 days. In addition, ropinirole treatment for 7 days suppressed auto-oxidation in mouse striatal homogenates, in contrast to the vehicle treatment. In conclusion, ropinirole was able to suppress auto-oxidation, most probably by increasing GSH levels due to an increase of GSH synthesis. In addition, it is likely that auto-oxidation was also suppressed by the activation of GSH-regulating enzymes such as GPx, GR, and GST in the mouse striatum. Thus, our results indicate that the GSH-activating effect of ropinirole may render this dopamine agonist beneficial as a neuroprotective drug.

AB - We have previously reported that ropinirole, a non-ergot dopamine agonist, has neuroprotective effects against 6-hydroxydopamine in mice based on in vivo antioxidant properties such as the glutathione (GSH)-activating effect. In the present study, we determined that the effects of ropinirole on the level of expression of GSH-related enzyme mRNA, these enzymes were shown to regulate GSH contents in the brain. This study focused on the mechanism of GSH enhancement by ropinirole. Striatal GSH contents were significantly increased by 7-day daily administration of ropinirole. Furthermore, the expression levels of γ-glutamylcysteine synthetase (γ-GCS), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST) mRNA increased following daily injections of ropinirole for 7 days. In addition, ropinirole treatment for 7 days suppressed auto-oxidation in mouse striatal homogenates, in contrast to the vehicle treatment. In conclusion, ropinirole was able to suppress auto-oxidation, most probably by increasing GSH levels due to an increase of GSH synthesis. In addition, it is likely that auto-oxidation was also suppressed by the activation of GSH-regulating enzymes such as GPx, GR, and GST in the mouse striatum. Thus, our results indicate that the GSH-activating effect of ropinirole may render this dopamine agonist beneficial as a neuroprotective drug.

KW - Dopamine D2 agonist

KW - Glutathione

KW - Non-ergot derivative

KW - Ropinirole

UR - http://www.scopus.com/inward/record.url?scp=0035007296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035007296&partnerID=8YFLogxK

U2 - 10.1023/A:1007672414239

DO - 10.1023/A:1007672414239

M3 - Article

VL - 26

SP - 31

EP - 36

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 1

ER -